Available:*
Library | Item Barcode | Call Number | Material Type | Item Category 1 | Status |
|---|---|---|---|---|---|
Searching... | 30000010079702 | HD9650.5 A46 2005 | Open Access Book | Book | Searching... |
On Order
Summary
Summary
Globalization has been a relatively recent phenomenon but it is having an immense impact on the chemical industry. The emergence of China as a major manufacturing and consumer economy has been particularly important in this respect.
This book sets straight many common misperceptions about employment in manufacturing and R&D, analyzes what future business changes to expect within the industry, and the role of the financial community in the industrys current wave of consolidations and divestitures. The author, who has worked as a senior executive in Fortune 500 companies as well as a CEO in small to medium size firms, comments from first-hand experience what has gone wrong in many firms today who are struggling with changes in the marketplace. He suggests courses of action for company management to take in order to thrive as well as survive in this new environment.
The pharmaceutical industry has become such a large component of the chemical industry that it is analyzed in a separate chapter, with in-depth reviews of major country and regional business climates. The authors have extensive experience in pharmaceutical business practices and technology initiatives. The rise of Asian pharmaceutical companies is reviewed and the movement of technology investments between geographic regions, particularly Europe and North America, is described and explained in comprehensive detail.
Finally, the business climate inside China is reviewed extensively, with particular note of future trends. The author reviews the markets in which China is not only a leading world manufacturer but also an enormous domestic consumer. He does not gloss over the problems of doing business in China but explains how to deal with them. The topic of Chinas rapidly growing energy needs is described in considerable detail. The success of China in emerging rapidly from a backward agrarian economy has been at a considerable social cost and the author does not gloss over this aspect while acknowledging the accomplishment.
Author Notes
Roger Jones is President of Franklin International LLC.
Reviews 1
Choice Review
It is unfortunate that publishable versions were not required for papers presented at the March 2005 ACS symposium, but those appearing in this symposium monograph have been enhanced by their authors for publication. Chapters are titled "The Chemical Industry in the 21st Century," "Research and Development in the Pharmaceutical Industry and Investment in Innovation," and "The China Challenge." China is obviously the 500-pound gorilla in the first two chapters. Investment in research and development and other business aspects in Asia are discussed, as well as US research and development in general. The material seems timely. Chapter 2 includes a discussion on stem cell research. The third chapter discusses the business climate in China in a number of product areas. A key issue is protection of intellectual property. A primer on Chinese culture and history is valuable. Outsourcing, a key topic, is cited only once in the index, although it is mentioned elsewhere in the text. Printing quality is not up to par, with much extra spacing. At the price, probably of interest only to universities and researchers interested in the Asian market. ^BSumming Up: Optional. Graduate students through professionals. R. E. Buntrock formerly, University of Maine
Table of Contents
| Preface | p. xi |
| 1 The Chemical Industry in the 21st Century | p. 1 |
| Is the U.S. Losing Its Manufacturing Base? | p. 2 |
| U.S. Manufacturing and China | p. 6 |
| The U.S. Chemical Industry | p. 11 |
| Employment: Overall and Chemistry Professionals | p. 16 |
| The Escalation of Competition | p. 22 |
| Industry and the Environment | p. 23 |
| Globalization and Regional Markets | p. 25 |
| Influence of the Financial Community | p. 27 |
| Duplicative or Differing Visions? | p. 31 |
| Is U.S. Chemical R&D in Decline? | p. 34 |
| What Might Be Done | p. 38 |
| Conclusions | p. 41 |
| References | p. 43 |
| 2 Research and Development in the Pharmaceutical Industry and Investment in Innovation | p. 47 |
| Introduction | p. 48 |
| Innovation Is the Life Blood of the Pharmaceutical Industry | p. 48 |
| Public Health Benefits from Innovation | p. 52 |
| Regions Want Pharmaceutical R&D | p. 53 |
| Venture Capitalists and Start-Up Enterprises | p. 54 |
| Constraints on Innovation: Cost Containment-Public Health and Public Benefit Collide | p. 55 |
| Intellectual Property Rights: When Innovation Cannot Be Turned into Profit | p. 56 |
| Effect of Globalization on R&D Activity | p. 56 |
| Trans-Oceanic Dynamics | p. 58 |
| U.S. R&D Dominance | p. 60 |
| State Investment Is Critical | p. 65 |
| California-Home of Biotech | p. 67 |
| Massachusetts-Another Innovation Driven Hotbed | p. 68 |
| States That Purposefully Create Innovation Centers | p. 70 |
| U.S. Private Investor Contribution to Stimulating R&D | p. 72 |
| European Complexity | p. 73 |
| Mounting Cost Pressures | p. 76 |
| Boosting Pharmaceutical Innovation in Europe | p. 76 |
| The Environment for R&D in the UK | p. 80 |
| The Environment for R&D in France | p. 83 |
| The Environment for R&D in Germany | p. 86 |
| The Environment for R&D in Spain | p. 88 |
| Japan | p. 90 |
| Emerging Asia | p. 92 |
| India Invests for the Future | p. 93 |
| Singapore | p. 95 |
| China | p. 96 |
| Stem Cell Research-An Example of Global Competition | p. 99 |
| Alternate Models of Investment | p. 101 |
| Conclusions | p. 103 |
| References | p. 104 |
| 3 The China Challenge | p. 111 |
| The Big Picture: Economic Trends and Implications | p. 112 |
| The World's Workshop | p. 113 |
| Automobiles | p. 115 |
| Telecommunications | p. 117 |
| Software | p. 120 |
| Power and Pollution | p. 124 |
| The Environmental Challenge | p. 131 |
| Rise of the Private Sector | p. 134 |
| The Entrepreneurial Challenge | p. 138 |
| The Rise of Chinese Multinationals | p. 141 |
| Key Market Entry Issues | p. 144 |
| Intellectual Property Protection | p. 144 |
| Guanxi | p. 148 |
| Homework | p. 150 |
| Differentiation and Pricing | p. 151 |
| Short- and Long-Term Strategy | p. 152 |
| Summary | p. 154 |
| Postscript | p. 155 |
| References | p. 159 |
| Indexes | |
| Author Index | p. 163 |
| Subject Index | p. 165 |
